Umicore issued an unexpected (qualitative) trading update in which it also reiterated its FY25 adjusted EBITDA guidance range of € 720-780m. Given the uncertain economic outlook, we decided to lower our forecast by 3% to € 734m, closer to the bottom end of the guidance range. We remind that Umicore recently organized a CMD, expressing the ambition to try to monetize past investments in Battery Materials, acknowledging that some additional capex and equity investment into the Ionway JV are still ...
A director at UCB SA bought 674 shares at 138.350EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Galapagos reported 1Q25 results with € 3.3b in cash and reiterated its cash burn guidance of € 175-225m (excl. restructuring costs). In the pipeline, the company provided more clarity on the path to market and selected MCL as lead indication, for which pivotal development is planned to begin in 2026. While Tecartus is already approved in that setting, it comes with burdensome toxicity and sales have plateaued. As such, we think GLPG5101's low rates of grade =3 CRS/ICANS could be a differentiator...
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Foun...
Galapagos rapporteert resultaten over het eerste kwartaal van 2025, recente hoogtepunten en verwachtingen op korte termijn Eerste Amerikaanse patiënt gedoseerd in ATALANTA-1 studie met GLPG5101 Mantelcellymfoom (MCL), een hematologische maligniteit met een hoge onvervulde behoefte, geselecteerd als hoofdindicatie voor het GLPG5101-programma; pivotale ontwikkeling gepland voor start in 2026, met als doel goedkeuring in 2028 Wijzigingen in het uitvoerend leidershap met het pensioen van Dr. Paul Stoffels als CEO na de benoeming van zijn opvolger, terwijl hij aanblijft als Voorzitter van ...
Galapagos announced two executive leadership updates including i) the appointment of Henry Gosebruch as CEO of the SpinCo following the previously announced company split, while ii) Paul Stoffels has informed the board of his intent to retire from his role as CEO upon appointment of a successor, and to remain as non-executive chair of the Galapagos board. We are encouraged by the appointment of a well experienced executive to lead SpinCo, while Paul Stoffels' decision to retire as CEO comes as a...
Galapagos Announces Executive Leadership Updates Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming pat...
Galapagos kondigt wijzigingen aan in uitvoerend leiderschap De heer Henry Gosebruch benoemd door de Raad van Bestuur van Galapagos als oprichtend CEO van het nieuw opgerichte SpinCo Dr. Paul Stoffels, Voorzitter en CEO van Galapagos, is van plan in pensioen te gaan als CEO na benoeming van een opvolger in de komende 12 maanden en is van plan om aan te blijven als Voorzitter van de Raad van Bestuur om de continuïteit van leiderschap en strategische guidance op lange termijn te waarborgen Mechelen, België; 21 april 2025, 22:10 CET; gereglementeerde informatie - voorwetenschap - Galapago...
A director at EXMAR NV bought 51,296 shares at 11.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.